FindTrial
Sign In

The association between intravenous iron and cardiovascular complications in hemodialysis patients

The association between intravenous iron and prescribe recombinant erythropoietin and cardiovascular events in hemodialysis patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201108049311N1
Enrollment
60
Registered
2020-12-16
Start date
2020-09-22
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease. Anemia in chronic kidney disease

Interventions

Intervention 1: Intervention group: High regimen of Iron: Including patients with <700 ferritin and/or <40% Iron saturation that will receive monthly 400 mg intravenous Iron for 6 months. Intervention

Sponsors

Personal expense
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Be volunteer to participate in the study Patients with end-stage renal disease that have undergone six months of their dialysis Age group of 18-80 years

Exclusion criteria

Exclusion criteria: >700 Ferritin level and/or >40% Iron saturation Having an active infection

Design outcomes

Primary

MeasureTime frame
Decreasing the required weakly dose of Erythropoietin. Timepoint: Monthly during 6 month prescription of intravenous Iron. Method of measurement: Performing blood test and ELISA method.;Reducing cardiovascular events. Timepoint: Monthly during 6 month prescription of intravenous Iron. Method of measurement: Investigating the incidence of chronic myocardial ischemia, cerebral stroke, heart failure and mortality rate.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farahnoosh Farnood

Tabriz University of Medical Sciences

farnood_farahnoosh@yahoo.com+98 41 3336 9331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026